PHIO (phiopharma.com) Margin bathi reged

Phio Pharmaceuticals develops innovative RNA drugs to combat cancer using a unique carrier-free gene delivery method. Robotic screening systems here accelerate the search for formulas by eliminating routine labor. However, the testing phase creates a dependency on capital in the absence of profit. On the GURU.Markets platform, the gross margin demonstrates current efficiency, where the indicator is fixed at 0.00.
Rincian metrik keuangan lan pasar RXi Pharmaceuticals (PHIO)

Gross margin measures the efficiency of covering direct production costs through revenue, allowing an investor to assess the pricing power and operational profitability of the business. Gross profit margin analysis helps determine the financial stability of Phio Pharmaceuticals (PHIO) during the development of the INTASYL platform, reflecting the company's ability to optimize costs while creating innovative immuno-oncology drugs.